{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:34:42Z","timestamp":1771364082688,"version":"3.50.1"},"reference-count":32,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["3\/1\/3\/WL\/JRF-2008\/MPD"],"award-info":[{"award-number":["3\/1\/3\/WL\/JRF-2008\/MPD"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PPL"],"published-print":{"date-parts":[[2020,2,10]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Host-directed therapies are a comparatively new and promising method for\nthe treatment of tuberculosis. A variety of host pathways, vaccines and drugs have the potential to\nprovide novel adjunctive therapies for the treatment of tuberculosis. In this connection, we have\nearlier reported the immunotherapeutic potential of N-formylated N-terminal peptide of glutamine\nsynthetase of Mycobacterim tuberculosis H37Rv (Mir SA and Sharma S, 2014). Now in the present\nstudy, we investigated the immunotherapeutic effect of N-terminally formylated internal-peptide 'f-\nMLLLPD' of mycobacterial glutamine synthetase (Rv2220) in mouse model of tuberculosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The N-terminally formylated peptide, f-MLLLPD was tested for its potential to generate\nReactive Oxygen Species (ROS) in murine neutrophils. Further, its therapeutic effect alone or in\ncombination with anti-tubercular drugs was evaluated in mouse model of tuberculosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The f-MLLLPD peptide treatment alone and in combination with ATDs reduced the\nbacterial load (indicated as colony forming units) in lungs of infected mice by 0.58 (p&lt;0.01) and\n2.92 (p&lt;0.001) log10 units respectively and in their spleens by 0.46 (p&lt;0.05) and 2.46 (p&lt;0.001)\nlog10 units respectively. In addition, the observed histopathological results correlated well with the\nCFU data.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion :<\/jats:title>\n<jats:p> The results of the current study show that f-MLLLPD peptide confers an additional\ntherapeutic efficacy to the anti-tuberculosis drugs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929866526666191028151615","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T15:30:36Z","timestamp":1575300636000},"page":"236-242","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Adjunctive Immunotherapeutic Efficacy of N-Formylated Internal Peptide of Mycobacterial Glutamine Synthetase in Mouse Model of Tuberculosis"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-1598","authenticated-orcid":true,"given":"Shabir Ahmad","family":"Mir","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Postgraduate Institute of Medical Education &Research (PGIMER), Chandigarh - 160012, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadhna","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Postgraduate Institute of Medical Education &Research (PGIMER), Chandigarh - 160012, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002152","volume":"13","author":"Houben R.M.","year":"2016","unstructured":"Houben R.M.; Dodd P.J.; The global burden of latent tuberculosis infection: A re-estimation using mathematical modelling. PLoS Med 2016,13(10)","journal-title":"PLoS Med"},{"key":"ref=2","unstructured":"WHO. Global Tuberculosis Report. World Health Organization 2018. Available from:"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.4049\/jimmunol.178.6.3806","volume":"178","author":"Doi T.","year":"2007","unstructured":"Doi T.; Yamada H.; Yajima T.; Wajjwalku W.; Hara T.; Yoshikai Y.; H2-M3-restricted CD8+ T cells induced by peptide-pulsed dendritic cells confer protection against Mycobacterium tuberculosis. J Immunol 2007,178(6),3806-3813","journal-title":"J Immunol"},{"key":"ref=4","year":"2007","unstructured":"Report of The Expert Consultation on\nImmunother-Apeutic Interventions for Tuberculosis Word Health Organization2007","journal-title":"Report of The Expert Consultation on\nImmunother-Apeutic Interventions for Tuberculosis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1476-8518-9-4","volume":"9","author":"Sheikh J.A.","year":"2011","unstructured":"Sheikh J.A.; Khuller G.K.; Verma I.; Immunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapy. J Immune Based Ther Vaccines 2011,9,4","journal-title":"J Immune Based Ther Vaccines"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1164\/rccm.2305001","volume":"168","author":"Barnes P.F.","year":"2003","unstructured":"Barnes P.F.; Immunotherapy for tuberculosis: Wave of the future or tilting at windmills? Am J Respir Crit Care Med 2003,168(2),142-143","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1750-9378-7-14","volume":"7","author":"F\u00e1varo W.J.","year":"2012","unstructured":"F\u00e1varo W.J.; Nunes O.S.; Seiva F.R.; Nunes I.S.; Woolhiser L.K.; Dur\u00e1n N.; Lenaerts A.J.; Effects of P-MAPA immunomodulator on toll-like receptors and p53: Potential therapeutic strategies for infectious diseases and cancer. Infect Agent Cancer 2012,7(1),14","journal-title":"Infect Agent Cancer"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/med.20214","volume":"32","author":"Hedayat M.","year":"2012","unstructured":"Hedayat M.; Takeda K.; Rezaei N.; Prophylactic and therapeutic implications of toll-like receptor ligands. Med Res Rev 2012,32(2),294-325","journal-title":"Med Res Rev"},{"key":"ref=9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002646","volume":"8","author":"Karmakar S.","year":"2012","unstructured":"Karmakar S.; Bhaumik S.K.; Paul J.; De T.; TLR4 and NKT cell synergy in immunotherapy against visceral leishmaniasis. PLoS Pathog 2012,8(4)","journal-title":"PLoS Pathog"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.intimp.2013.09.010","volume":"18","author":"Mir S.A.","year":"2014","unstructured":"Mir S.A.; Sharma S.; Immunotherapeutic potential of N-formylated peptides of ESAT-6 and glutamine synthetase in experimental tuberculosis. Int Immunopharmacol 2014,18(2),298-303","journal-title":"Int Immunopharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/embor.2011.157","volume":"12","author":"Arnoult D.","year":"2011","unstructured":"Arnoult D.; Soares F.; Tattoli I.; Girardin S.E.; Mitochondria in innate immunity. EMBO Rep 2011,12(9),901-910","journal-title":"EMBO Rep"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.2174\/092986712799828283","volume":"19","author":"Jones R.M.","year":"2012","unstructured":"Jones R.M.; Mercante J.W.; Neish A.S.; Reactive oxygen production induced by the gut microbiota: Pharmacotherapeutic implications. Curr Med Chem 2012,19(10),1519-1529","journal-title":"Curr Med Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1034\/j.1600-065X.2000.917309.x","volume":"173","author":"Medzhitov R.","year":"2000","unstructured":"Medzhitov R.; Janeway C.; Innate immune recognition: mechanisms and pathways. Immunol Rev 2000,173,89-97","journal-title":"Immunol Rev"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167529","volume":"11","author":"Winther M.","year":"2016","unstructured":"Winther M.; Holdfeldt A.; Gabl M.; Wang J.M.; Forsman H.; Dahlgren C.; Formylated MHC class Ib binding peptides activate both human and mouse Neutrophils primarily through formyl peptide receptor 1. PLoS One 2016,11(12)","journal-title":"PLoS One"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3109\/08923979909007117","volume":"21","author":"Panaro M.A.","year":"1999","unstructured":"Panaro M.A.; Mitolo V.; Cellular responses to FMLP challenging: A mini-review. Immunopharmacol Immunotoxicol 1999,21(3),397-419","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1128\/AAC.47.8.2545-2550.2003","volume":"47","author":"Fu H.","year":"2003","unstructured":"Fu H.; Dahlgren C.; Bylund J.; Subinhibitory concentrations of the deformylase inhibitor actinonin increase bacterial release of neutrophil-activating peptides: A new approach to antimicrobial chemotherapy. Antimicrob Agents Chemother 2003,47(8),2545-2550","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1084\/jem.189.4.657","volume":"189","author":"Gao J.L.","year":"1999","unstructured":"Gao J.L.; Lee E.J.; Murphy P.M.; Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor. J Exp Med 1999,189(4),657-662","journal-title":"J Exp Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/j.micinf.2006.03.020","volume":"8","author":"Colmone A.","year":"2006","unstructured":"Colmone A.; Wang C.R.; H2-M3-restricted T cell response to infection. Microbes Infect 2006,8(8),2277-2283","journal-title":"Microbes Infect"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1016\/j.vaccine.2013.04.005","volume":"31","author":"Mir S.A.","year":"2013","unstructured":"Mir S.A.; Sharma S.; Role of MHC class Ib molecule, H2-M3 in host immunity against tuberculosis. Vaccine 2013,31(37),3818-3825","journal-title":"Vaccine"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1084\/jem.190.2.195","volume":"190","author":"Kerksiek K.M.","year":"1999","unstructured":"Kerksiek K.M.; Busch D.H.; Pilip I.M.; Allen S.E.; Pamer E.G.; H2-M3-restricted T cells in bacterial infection: Rapid primary but diminished memory responses. J Exp Med 1999,190(2),195-204","journal-title":"J Exp Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/0092-8674(95)90037-3","volume":"82","author":"Wang C.R.","year":"1995","unstructured":"Wang C.R.; Casta\u00f1o A.R.; Peterson P.A.; Slaughter C.; Lindahl K.F.; Deisenhofer J.; Nonclassical binding of formylated peptide in crystal structure of the MHC class Ib molecule H2-M3. Cell 1995,82(4),655-664","journal-title":"Cell"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"F35","DOI":"10.1084\/jem.193.10.F35","volume":"193","author":"Lauvau G.","year":"2001","unstructured":"Lauvau G.; Pamer E.G.; CD8 T cell detection of bacterial infection: sniffing for formyl peptides derived from Mycobacterium tuberculosis. J Exp Med 2001,193(10),F35-F39","journal-title":"J Exp Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/ni1449","volume":"8","author":"Khader S.A.","year":"2007","unstructured":"Khader S.A.; Bell G.K.; Pearl J.E.; Fountain J.J.; Rangel-Moreno J.; Cilley G.E.; Shen F.; Eaton S.M.; Gaffen S.L.; Swain S.L.; Locksley R.M.; Haynes L.; Randall T.D.; Cooper A.M.; IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007,8(4),369-377","journal-title":"Nat Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.imlet.2013.12.007","volume":"158","author":"Mir S.A.","year":"2014","unstructured":"Mir S.A.; Verma I.; Sharma S.; Immunotherapeutic potential of recombinant ESAT-6 protein in mouse model of experimental tuberculosis. Immunol Lett 2014,158(1-2),88-94","journal-title":"Immunol Lett"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.4049\/jimmunol.179.6.3570","volume":"179","author":"Sukhumavasi W.","year":"2007","unstructured":"Sukhumavasi W.; Egan C.E.; Denkers E.Y.; Mouse neutrophils require JNK2 MAPK for Toxoplasma gondii-induced IL-12p40 and CCL2\/MCP-1 release. J Immunol 2007,179(6),3570-3577","journal-title":"J Immunol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.immuni.2009.09.016","volume":"31","author":"Zhang X.","year":"2009","unstructured":"Zhang X.; Majlessi L.; Deriaud E.; Leclerc C.; Lo-Man R.; Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils. Immunity 2009,31(5),761-771","journal-title":"Immunity"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1378\/chest.09-0903","volume":"137","author":"Eum S.Y.","year":"2010","unstructured":"Eum S.Y.; Kong J.H.; Hong M.S.; Lee Y.J.; Kim J.H.; Hwang S.H.; Cho S.N.; Via L.E.; Barry C.E.; III Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 2010,137(1),122-128","journal-title":"Chest"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1002\/eji.201040433","volume":"40","author":"Redford P.S.","year":"2010","unstructured":"Redford P.S.; Boonstra A.; Read S.; Pitt J.; Graham C.; Stavropoulos E.; Bancroft G.J.; O\u2019Garra A.; Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur J Immunol 2010,40(8),2200-2210","journal-title":"Eur J Immunol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.micinf.2010.01.014","volume":"12","author":"Mader D.","year":"2010","unstructured":"Mader D.; Rabiet M.J.; Boulay F.; Peschel A.; Formyl peptide receptor-mediated proinflammatory consequences of peptide deformylase inhibition in Staphylococcus aureus. Microbes Infect 2010,12(5),415-419","journal-title":"Microbes Infect"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ijantimicag.2009.04.005","volume":"34","author":"Sharma A.","year":"2009","unstructured":"Sharma A.; Sharma S.; Khuller G.K.; Kanwar A.J.; \n                        In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv. Int J Antimicrob Agents 2009,34(3),226-230","journal-title":"Int J Antimicrob Agents"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jinf.2010.03.009","volume":"60","author":"Sharma A.","year":"2010","unstructured":"Sharma A.; Khuller G.K.; Kanwar A.J.; Sharma S.; Therapeutic potential of peptide deformylase inhibitors against experimental tuberculosis. J Infect 2010,60(6),498-501","journal-title":"J Infect"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1128\/AAC.46.9.2765-2771.2002","volume":"46","author":"Bulatovic V.M.","year":"2002","unstructured":"Bulatovic V.M.; Wengenack N.L.; Uhl J.R.; Hall L.; Roberts G.D.; Cockerill F.R.; Rusnak F.; Oxidative stress increases susceptibility of Mycobacterium tuberculosis to isoniazid. Antimicrob Agents Chemother 2002,46(9),2765-2771","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Protein &amp; Peptide Letters"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/176250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T13:48:39Z","timestamp":1583416119000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/176250\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929866526666191028151615","relation":{},"ISSN":["0929-8665"],"issn-type":[{"value":"0929-8665","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}